Literature DB >> 16138249

Possible genotype-phenotype correlations in children with mild clinical course of Canavan disease.

U Tacke1, H Olbrich, J O Sass, A Fekete, J Horvath, S Ziyeh, W J Kleijer, M-O Rolland, S Fisher, S Payne, E Vargiami, D I Zafeiriou, H Omran.   

Abstract

Canavan disease is characterised as a rare, neurodegenerative disease that usually causes death in early childhood. It is an autosomal recessive disorder due to an aspartoacylase (ASPA) deficiency. The causative gene has been mapped to chromosome 17 pter-p13. Here we describe three affected children from two Greek families with an unusually mild course of Canavan disease. All children presented with muscular hypotonia and macrocephaly. Diagnosis was based on elevated N-acetylaspartate in urine, reduced aspartoacylase activity in fibroblasts, and marked white matter changes on cerebral imaging. All three affected individuals exhibited continuous psychomotor development without any regression. Genetic analyses revealed compound heterozygous mutations (Y288 C; F295 S) in two individuals. The Y288 C variant was previously described in a child with macrocephaly, mild developmental delay, increased signal intensity in the basal ganglia, partial cortical blindness and retinitis pigmentosa, and slightly elevated N-acetylaspartate in the urine. Demonstration of the same variant in two unusually mildly affected Canavan disease patients and absence of this variant in 154 control chromosomes suggest a possible pathogenic role in mild Canavan disease. In the third individual, two homozygous sequence variants were identified, which comprise the known G274R mutation and a novel K213E variant.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16138249     DOI: 10.1055/s-2005-865865

Source DB:  PubMed          Journal:  Neuropediatrics        ISSN: 0174-304X            Impact factor:   1.947


  7 in total

1.  Relationship between enzyme properties and disease progression in Canavan disease.

Authors:  Stephen Zano; Yasanandana S Wijayasinghe; Radhika Malik; Joshua Smith; Ronald E Viola
Journal:  J Inherit Metab Dis       Date:  2012-08-01       Impact factor: 4.982

2.  A missense mutation (p.G274R) in gene ASPA causes Canavan disease in a Pakistani family.

Authors:  Rashida Hussain; Shakeela Daud; Naseebullah Kakar; Adeel Ahmad; Abdul Hameed Baloch; Abdul Malik Tareen; Muhammad Azam Kakar; Jamil Ahmad
Journal:  Mol Biol Rep       Date:  2012-01-05       Impact factor: 2.316

3.  Structure of aspartoacylase, the brain enzyme impaired in Canavan disease.

Authors:  Eduard Bitto; Craig A Bingman; Gary E Wesenberg; Jason G McCoy; George N Phillips
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-28       Impact factor: 11.205

4.  Aspartoacylase-lacZ knockin mice: an engineered model of Canavan disease.

Authors:  Nadine Mersmann; Dmitri Tkachev; Ruth Jelinek; Philipp Thomas Röth; Wiebke Möbius; Torben Ruhwedel; Sabine Rühle; Wolfgang Weber-Fahr; Alexander Sartorius; Matthias Klugmann
Journal:  PLoS One       Date:  2011-05-20       Impact factor: 3.240

5.  Mutational analysis of aspartoacylase: implications for Canavan disease.

Authors:  Jeremy R Hershfield; Nagarajan Pattabiraman; Chikkathur N Madhavarao; M A Aryan Namboodiri
Journal:  Brain Res       Date:  2007-03-03       Impact factor: 3.252

6.  Clinically Distinct Phenotypes of Canavan Disease Correlate with Residual Aspartoacylase Enzyme Activity.

Authors:  Marisa I Mendes; Desirée Ec Smith; Ana Pop; Pascal Lennertz; Matilde R Fernandez Ojeda; Warsha A Kanhai; Silvy Jm van Dooren; Yair Anikster; Ivo Barić; Caroline Boelen; Jaime Campistol; Lonneke de Boer; Ariana Kariminejad; Hulya Kayserili; Agathe Roubertie; Krijn T Verbruggen; Christine Vianey-Saban; Monique Williams; Gajja S Salomons
Journal:  Hum Mutat       Date:  2017-02-14       Impact factor: 4.878

7.  Increasing N-acetylaspartate in the Brain during Postnatal Myelination Does Not Cause the CNS Pathologies of Canavan Disease.

Authors:  Abhilash P Appu; John R Moffett; Peethambaran Arun; Sean Moran; Vikram Nambiar; Jishnu K S Krishnan; Narayanan Puthillathu; Aryan M A Namboodiri
Journal:  Front Mol Neurosci       Date:  2017-06-02       Impact factor: 5.639

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.